Epilepsy Monitoring Devices Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product (Wearable Devices, Conventional Devices, and Implantable Devices), By Technology (Vagus Nerve Stimulation (VNS), Responsive Neurostimulation, Deep Brain Stimulation, and Accelerometry), By End User (Hospitals and Clinics, Ambulatory Surgery Centers, Neurology Centers, Diagnostic Centers, and Home Care Settings) and Region 

Epilepsy Monitoring Devices Market size was valued at US$ 525 million in 2023 and is poised to grow at a significant CAGR of 4.9% from 2024–2030. Epilepsy is a neurological disorder, that affects the central nervous system in which brain activity becomes abnormal, causing seizures or periods of unusual behavior, sensations, temporary confusion, uncontrollable jerking movements of arms and legs, and loss of awareness. Anyone can develop epilepsy irrespective of males and females of all races, ethnic backgrounds, and ages.

According to WHO, around 50 million people worldwide have epilepsy, and nearly 80% of people with epilepsy live in low- and middle-income countries. It is estimated that up to 70% of people living with epilepsy could live seizure-free if properly diagnosed and treated. The increasing prevalence of epilepsy and incidence of head injuries, brain cancer, and infections are driving the market share. Around 5 million people are diagnosed with epilepsy each year worldwide. Moreover, the rise in research & development activities with the immense investment and the awareness about epilepsy monitoring devices is expected to increase the epilepsy devices market demand. Various awareness programs organized by organizations and government initiatives will further increase the awareness and growth of the market. 

However, the high cost of complex epilepsy monitoring procedures and devices is a significant restrain that limits the market growth. For instance, handling MEG devices is very challenging for healthcare facilities in countries that have implemented this monitoring equipment. Although increasing demand for non-invasive and minimally invasive devices shows the opportunity in the market. Invasive monitoring is a very risky, intricate, and painful process that needs direct intervention with the brain's sensitive tissues. As a result, patients and doctors are more interested in using minimally or non-invasive epilepsy monitoring technologies.  

Key Developments

• In Feb 2022, Angelini Pharma, an international Italian pharmaceutical company, announced that it would provide patients and healthcare professionals with innovative solutions to improve the care of patients with epilepsy.
• In January 2021, Nihon Kohden launched disposable EEG electrodes to help prevent cross-contamination between patients and healthcare workers.